^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    NRF2 activator

    Related drugs:
    1d
    A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Biogen | Trial primary completion date: Feb 2030 --> Sep 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    Skyclarys (omaveloxolone)
    13d
    Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Centre Hospitalier Universitaire de Nice | Not yet recruiting --> Recruiting | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Skyclarys (omaveloxolone)
    14d
    Lycorine suppresses DPP3-mediated Nrf2 signaling, thereby reducing SLC7A11 levels to trigger ferroptosis in colorectal cancer cells. (PubMed, Phytomedicine)
    Lycorine can directly bind to and inhibit DPP3, thereby blocking the Nrf2 signaling pathway and downregulating SLC7A11. This disruption of GSH metabolism leads to the accumulation of ROS and iron overload, ultimately inducing ferroptosis in CRC cells.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11) • DPP3 (Dipeptidyl Peptidase 3)
    16d
    RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells. (PubMed, Hepat Oncol)
    Inhibition of p38 partially restored cell viability and reduced apoptosis. RTA-408 suppresses HCC cell survival through a p38-dependent stress response associated with NRF2 activation and LC3B/p62 accumulation.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
    |
    Skyclarys (omaveloxolone)
    18d
    A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants (clinicaltrials.gov)
    P1, N=26, Recruiting, AnnJi Pharmaceutical Co., Ltd.
    New P1 trial
    19d
    DARLENE: DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL (clinicaltrials.gov)
    P2, N=192, Recruiting, University Hospital, Lille | Not yet recruiting --> Recruiting
    Enrollment open
    19d
    Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes (clinicaltrials.gov)
    P2/3, N=96, Recruiting, Nanjing Medical University
    New P2/3 trial
    25d
    PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. (PubMed, Leukemia)
    Notably, combined treatment with the PRMT5 inhibitor GSK3326595 and DMF synergistically enhances anti-tumor activity in a patient-derived xenograft (PDX) model. These findings reveal a previously unrecognized PRMT5-ATF5-SLC7A11 axis that drives ferroptosis resistance in B-cell lymphomas and provide a strong rationale for targeting PRMT5 to potentiate ferroptosis-based therapies in relapsed or refractory disease.
    Journal
    |
    PRMT5 (Protein Arginine Methyltransferase 5) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4)
    |
    pemrametostat (GSK3326595)
    2ms
    Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria (clinicaltrials.gov)
    P2, N=240, Completed, Curacle Co., Ltd. | Recruiting --> Completed | Phase classification: P2b --> P2 | Trial completion date: Sep 2024 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Nov 2025
    Trial completion • Phase classification • Trial completion date • Trial primary completion date
    |
    dimethyl fumarate (CU01)
    2ms
    RRx-001 inhibits G6PD to deplete NADPH and trigger disulfidptosis coupled with DAMP-mediated immunogenic cell death in hepatocellular carcinoma. (PubMed, Cell Death Discov)
    In vivo, RRx-001 significantly inhibits tumor growth, enhances T-cell infiltration, promotes M1 macrophage polarization, downregulates PD-L1 expression, and strengthens anti-tumor immunity through T cell-related pathways. With both metabolic and immunomodulatory effects, RRx-001 provides a basis for novel HCC therapies, and future research could explore its synergistic effects with immune checkpoint inhibitors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • HMGB1 (High Mobility Group Box 1) • G6PD (Glucose-6-Phosphate Dehydrogenase)
    |
    PD-L1 expression
    |
    nibrozetone (RRx-001)
    2ms
    Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation. (PubMed, Mol Oncol)
    We found a p53-mediated downregulation of the Solute Carrier Family 7 Member 11 (SLC7A11)/Cystine/Glutamate Transporter (xCT) expression and glutathione levels. Our results suggest that combined administration of DMF and cisplatin, by targeting the dependency of cervical cancer cells on glutathione and (re)activating p53, represents a promising anticancer therapeutic strategy.
    Journal
    |
    SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    cisplatin
    2ms
    VOYAGE: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) (clinicaltrials.gov)
    P3, N=185, Not yet recruiting, Biogen
    New P3 trial
    |
    fingolimod